Daiichi Sankyo claimed on May 22 that the company believes former shareholders of its subsidiary Ranbaxy Laboratories, of India, which recently pleaded guilty to Good Manufacturing Practice (GMP) violations and data falsification, hid information about the US Department of Justice…
To read the full story
Related Article
- Daiichi Sankyo Sued by Malaysia Hospital Group over TOB Interference
November 28, 2023
BUSINESS
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
- Velcade Generics Widen Labels to Mantle Cell Lymphoma
December 18, 2025
- Kowa Releases Glaucoma Drug Gla-Alpha in Malaysia
December 18, 2025
- Xarelto Generics Win Adult, Pediatric VTE Indication Expansions
December 18, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





